NR1H4 and metabolic dysfunction-associated steatohepatitis: In addition, INT-767, an FXR/TGR5 dual agonist, shows lowered lipid accumulation, inflammation, and fibrosis in various in vitro models [54,55,56], while studies on individuals with NASH are still ongoing [55] (Table 1).